

SEPL/SE/May/26-27

20th May 2026

**The General Manager,
Corporate Relations/Listing
Department
BSE Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai – 400 001
Scrip Code: 501423**

**The Manager,
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051
Scrip Code: SHAILY**

Subject: Press Release

Dear Sir/Madam,

We are attaching herewith copy of the Press Release titled “**Shaily Engineering Plastics Limited Announces Regulatory Approval & Launch of Customer Combination Product Incorporating its ShailyPen Neo Device Technology**” which is self-explanatory.

The same is submitted for public dissemination and for your records.

Thanking You.

Yours Sincerely,

For Shaily Engineering Plastics Limited

**Harish Punwani
Company Secretary & Compliance Officer
ICSI M. No. A50950**

PRESS RELEASE | 20 May 2026, Vadodara, India

Shaily Engineering Plastics Limited Announces Regulatory Approval & Launch of Customer Combination Product Incorporating its ShailyPen Neo™ Device Technology

USFDA Tentative Approval, Health Canada Notice of Compliance, and Indian Regulatory Approval Secured for Generic Semaglutide Injection Incorporating the ShailyPen Neo™ Spring-Driven Variable and Fixed Dose Pen Injector Platform

Shaily Engineering Plastics Limited (“Shaily”), a leading developer and manufacturer of drug delivery systems, today announced that its strategic partner **Orbicular Pharmaceutical Technologies in partnership with its Customer** has launched a generic version of Semaglutide injection in Canada, incorporating Shaily’s proprietary spring-driven **ShailyPen Neo™** pen platform. The combination product has been commercially available in India since March 2026 and has received USFDA Tentative Approval.

ShailyPen Neo™ is among a rare class of commercially available spring-driven pen injectors globally — a high-performance, variable and fixed dose platform offering full compatibility with ISO-standard 3 mL cartridges (3 mL and 1.5 mL fill). Shaily’s role in this program relates to full design and development, and manufacturing and supply of the device components used in the approved combination product.



ShailyPen Neo™
Spring-Driven
Variable & Fixed Dose
Pen Injector

Regulatory Approvals	Device Platform	Cartridge Format
USFDA TA • Health Canada • India CDSCO	ShailyPen Neo™ • Variable & Fixed Dose	ISO 3 mL • 1.5 mL fill

“This achievement is one we carry with a great deal of humility. ShailyPen Neo™ did not happen by accident — spring-driven pen injector technology sits within a highly restricted IP environment, and bringing a platform of this caliber to regulatory approval was never going to be easy. We recognized early that spring-actuated pen injectors would become a critical enabler in injectable therapies and made a genuinely bold bet: full-scale investment from design through to industrial manufacturing. What got us here was not boldness alone — it was patience, precision, and an unshakeable belief in what we were building. I am deeply grateful to our customers who believed in us and chose to build with us — your confidence in Shaily has pushed us to be better at every step. And to every member of the Shaily team who poured their expertise and commitment into this program: you are the reason we are here.”

— Amit Sanghvi, Managing Director, Shaily Engineering Plastics Limited



CIN # L51900GJ1980PLC065554

Regd. Office :
Survey No. 363, 364 & 366,
At & Po. Ramia 391780, Ta-Savli,
Dist. Vadodara, Gujarat, India.
Phone : +91-2667-244307/361
Fax : +91-2667-244379
E-Mail : ramia.plant@shaily.com

Ramia Plant :
Survey No. 366,
At & Po. Ramia 391780, Ta-Savli,
Dist. Vadodara Gujarat, India.
Phone : +91-2667-244372
Fax : +91-2667-244379
E-Mail : ramia.plant@shaily.com

Correspondence Address :
8, J. P. Nagar, Old Pancha Road
Vadodara - 390 015 Gujarat, India
Phone : +91-265-2339706
Fax No. : +91-265-2339793
E-Mail : sales@shaily.com
Visit us at : www.shaily.com

About Shaily Engineering Plastics Limited

Shaily Engineering Plastics Limited operates across 3 major industry verticals specializing in manufacturing high precision components and assemblies using high performance engineering polymers. Shaily's healthcare business specifically specializes in the design, development, and precision manufacturing of complex drug delivery systems such as pen injectors, autoinjectors, and specialty drug delivery devices for the global pharmaceuticals. With a proprietary portfolio of drug delivery device platforms and manufacturing facilities accredited to MDSAP, and ISO 13485:2022, Shaily partners with leading pharmaceutical companies to co-develop and commercially supply validated combination product solutions that meet the stringent regulatory requirements of international healthcare markets.

Shaily is listed on the National Stock Exchange of India (NSE: SHAILY) and BSE Limited (Scrip Code: 501423).

For more information, Company website - www.shaily.com

For further details, please contact:

Shaily Engineering Plastics Limited

CIN: L51900GJ1980PLC065554

Name: Mr. Sanjay Shah /Ms. Ruchita Sharma

Email: sanjay@shaily.com / ruchita.sharma@shaily.com

www.shaily.com

Investor Enquiries

Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Name: Mr. Deven Dhruva / Ms. Krisha Shrimankar

Email: deven.dhruva@sgapl.net / krisha.shrimankar@sgapl.net

Tel: +91 98333 73300 / +91 87797 99281

Disclaimer: This press release may contain forward-looking statements relating to business opportunities, commercial supply, future revenues, market expansion, and strategic collaborations. Actual results may differ materially due to various business, regulatory, contractual, and market factors. The Company undertakes no obligation to update such statements except as required under applicable law.